Ophthalmic fluid delivery system

Abstract

An ophthalmic fluid delivery environment that includes a human eye in an open position and an atomizer having a nozzle aimed at the human eye in the open position, wherein a plume of ophthalmic fluid mist is directed by the nozzle so that the mist is received by the human eye in the open position and the received mist has a momentum that is insufficient to trigger to at least one of an ocular blink reflex and a lacrimation reflex of the human eye that receives the mist.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]The present application is a divisional application of U.S. patent application Ser. No. 10 / 851,611, filed on May 20, 2004, which claims priority under 35 U.S.C. § 119(e) to both U.S. Provisional Application No. 60 / 485,305, filed on Jul. 3, 2003 and U.S. Provisional Application No. 60 / 471,883, filed on May 20, 2003, wherein each of the above mentioned U.S. Patent and U.S. Provisional Applications are incorporated herein by reference.FIELD OF THE INVENTION[0002]The present invention relates to drug delivery devices for dispensing liquid as an aerosol or atomized mist and, more particularly, for dispensing medicaments to the eye.BACKGROUND OF THE INVENTION[0003]Presently, conventional eye drops are the standard means of delivering medicaments to the eye. This means of ophthalmic drug delivery, however, has numerous problems. For example, the average eye drop (approximately 50 micro liters) far exceeds the eye's capacity (7 micro liters in th...

AI Technical Summary

Benefits of technology

[0014]It would be beneficial to provide a system for applying the desired small amounts (7 to 10 micro liters) of optical medication, along

Problems solved by technology

This means of ophthalmic drug delivery, however, has numerous problems.

This results in a brief period of massive over-dosage, which is quickly cleared by reflex lacrimation, blinking and nasolacrimal drainage, resulting in sub-therapeutic drug levels until the next medication application.

This approach represents very inefficient pharmacokinetics.

Attempts to prolong ocular contact time by various adaptations, such as the use of particulate suspensions, have led to other drawbacks including ocular irritation and excessively slow drug release.

Ointments and gels, though providing prolonged contact time, create obvious visual disturbances.

Further, local irritations and toxicities often result from the regular use of eye drops.

These situations vary widely depending on the pharmacologic agent, preservatives and other additives being used, but this is clearly a very non-physiologic and inefficient system of medication administration.

Chronic use of eye drops for such conditions as glaucoma and prolonged infections and inflammations can, in fact, cause substantial morbidity.

Additionally, serious and even fatal reactions to sympathomimetic and beta-adrenergic blocking agents have occurred as a result of systemic absorption of eye drops via nasolacrimal drainage.

Besides the above issues, there are a great many difficulties that patients experience with the mechanics of eye drop administration.

Elderly patients, the largest group of eye drop users, often have hand-eye coordination problems, tremors or arthritis, affecting the hands and / or the cervical spine, making eye drop administration difficult if not impossible.

Many users report that they have trouble keeping track of their regimens and often repeat doses or miss them entirely, suffering potential consequences in either event.

Further, pediatric patients, often unable to comprehend the reasons and benefits behind the administration of eye medication, often fight such application, typically resulting in underdosing due to the patient's attempts to prevent the eye drops from being administered, or overdosing, as a result of the administrator's attempt to ensure that sufficient dosage is being applied.

It is sometimes difficult to tell if the drop was properly instilled.

Direct application to the cornea can result in the drop “bouncing” from the eye with little or no benefit.

Also, many eye drop bottles are fabricated in such a way that loss is unavoidable as soon as the dropper is tilted.

All of the above represent needless waste of expensive medication (many glaucoma medications cost $70-$80 for a 5 ml bottle) and also increased the risk of side effects, while actually reducing the therapeutic benefit.

With an estimate of 25 million users of eye drops in the United States alone, the magnitude of the public health issue is considerable.

Which have inherent drawbacks relating to difficulties with calibrating the flow velocity, volume and particle size of the emitted spray.

Furthermore, the surface tension of a standard drop is a barrier to “mixing” and tear film incorporation.

In the professional office setting, this problem has led to many documented epidemics of viral keratoconjunctivitis.

Images